Introduction

StanoloneDHT2

Factory 1

musclepic 1

Products Description

1. Product Overview and Specifications

100mg/ml, 10ml oil solution Stanolone refers to an oil solution containing 100mg of the active ingredient dihydrotestosterone per ml, with a total volume of 10 ml. This product is typically packaged in single-use or multiple-use sterile glass vials for downstream formulation, clinical formulation, or research use. The choice of oil carrier, excipient type, and preparation process directly impact the final product's appearance, stability, and pharmacokinetic properties.

2. Classification (Based on Usage and Quality)

1. Pharmaceutical-grade products: Injectable preparations or APIs that meet pharmacopoeial or NMPA requirements and must pass stringent testing for sterility, endotoxins, content, and impurity limits. They are typically used for approved medical indications or in regulated clinical trials.

2. Research-grade products: Reagents used in in vitro and in vivo studies (animal testing, pharmacodynamics, or toxicology studies). They meet higher purity and quality control standards than general industrial-grade products, but may not meet all pharmacopoeial standards for injectables.

3. Veterinary or Industrial-Grade Products: These products may be used for animal research or non-human applications, and their quality control requirements differ from those of pharmaceutical-grade products.

4. Illegal or Gray Market Products: The composition, purity, sterility, and labeling of these products may be questionable, posing significant safety risks.

3. Physicochemical Properties (High-Level Description)

Dihydrotestosterone is a highly hydrophobic steroidal compound with a molecular formula of C₁₆H₃₀O₂ and a molecular weight of approximately 290.45 g·mol⁻¹. As a natural androgen metabolite, it is highly soluble in non-polar solvents, readily soluble in vegetable oils (such as sesame oil, cottonseed oil, and MCT) and organic solvents (such as ethanol, acetone, and ethyl acetate), but extremely insoluble in water. Chemically, it is sensitive to light, heat, and oxidation, and exposure to strong light, high temperature, or high humidity accelerates degradation or discoloration. Due to its lipid solubility, an oil carrier can prolong drug release and improve drug uniformity in the oil phase.

4. Appearance and Color Characteristics

Solid raw materials (powders) are typically white to off-white crystalline or amorphous powders. A distinct yellow-brown or mottled color often indicates oxidation, impurities, or improper storage. After being formulated into an oily formulation, a qualified product is generally a clear liquid or slightly yellowish oily solution. Colors ranging from nearly transparent to light amber are considered normal, depending on the excipients (carrier oil, solvent). Turbidity, precipitation, particles, or a dark brown color are considered unacceptable or indicative of failure, requiring further testing to rule out degradation or microbial contamination.

5. Formulation Characteristics and Common Excipients (Not Process Guidance)

Common inactive ingredients used in injectable oily formulations include vegetable oils (such as sesame oil, cottonseed oil, and MCT) as the primary carrier, benzyl benzoate (used as a solvent or stabilizer), and benzyl alcohol (used as a preservative or antioxidant, depending on the formulation). The choice of excipients influences viscosity, solubility, injection comfort (for clinical use), and long-term stability. Important Disclaimer: The following does not provide operational details such as preparation, mixing ratios, or process flow. It only describes common excipient types and their effects on the properties of the final product.

6. Advantages and Potential Uses (from a Pharmacological and Application Perspective)

1. Strong androgenic Activity: DHT has a high affinity for androgen receptors and can exert significant androgen-like effects, promoting tissue responses related to protein synthesis and androgenic physiological changes.

2. Non-aromatization: DHT itself cannot be converted into estrogen, thus theoretically avoiding or significantly reducing estrogen-related side effects caused by aromatization (such as edema and estrogen-induced breast development).

3. Promoting a "hardening" effect: In bodybuilding/plasty reviews, DHT drugs are often described as improving muscle definition and a "hard" feeling, rather than significantly increasing weight or causing water retention. 4. Medical Use (Restricted): Historically and in some regions, androgens or their analogs have been used to treat certain androgen deficiencies, specific anemias, or other endocrine indications. Specific indications and regulatory approvals vary by country/region.

It is important to emphasize that the "advantages" described above are described from a pharmacological perspective and do not constitute a clinical recommendation or encourage unauthorized use.

7. Adverse Reactions and Safety Risks (Must Take Full Account)

1. Androgen-Related Adverse Reactions: Acne, increased sebum, increased body/facial hair, accelerated male pattern baldness (in genetically susceptible individuals), and the risk of prostate irritation or hyperplasia. Exposure in women may result in signs of virilization (thickening of the vocal cords, increased body hair, menstrual irregularities, etc.), some of which may be irreversible.

2. Reproductive and Endocrine Suppression: Exogenous strong androgens can suppress the hypothalamic-pituitary-testicular axis. Long-term use may lead to decreased endogenous testosterone secretion and suppressed spermatogenesis, impairing fertility. 3. Cardiovascular and Metabolic Risks: Long-term or high-dose use of androgen drugs can cause adverse lipid profiles (e.g., high LDL cholesterol, low HDL cholesterol), blood pressure fluctuations, and other changes in cardiovascular risk markers.

4. Local and Formulation-Related Risks: If the injectable formulation is not sterile or improperly handled, there is a risk of injection site infection, tissue inflammation, granulomas, or systemic infection. The presence of particles or precipitation in the oil formulation also increases the likelihood of adverse reactions.

5. Other Risks: Mood swings, changes in aggression, sleep and metabolic abnormalities, etc.

In summary, a thorough risk-benefit assessment must be made before use, and any clinical use should be conducted under regulatory medical supervision.

8. Key Quality Control and Testing Points (for Professionals and Regulators)

For injectable oil formulations, key quality control items include, but are not limited to: visual inspection, assay (HPLC or equivalent), analysis of relevant impurities and degradation products, sterility testing, bacterial endotoxin (LAL) testing, particle testing, pH and viscosity testing, and excipient residue and stability testing. Qualified production should follow Good Manufacturing Practices (GMP), and batch records and inspection reports should be retained.

9. Storage, Stability, and Shelf Life Tips

Dihydrotestosterone oil should be stored in a sealed container away from light, heat, and humidity. The specific storage temperature and shelf life are determined by the manufacturer based on stability testing. Unopened, it should be stored according to label instructions. Once opened, it should be used within a short period of time and adhere to aseptic handling and storage conditions. If the liquid becomes turbid, precipitated, or has an abnormal color, discontinue use and submit for inspection.

10. Regulatory, Ethical, and Compliance Considerations

Regulation of anabolic steroids and androgenic preparations varies significantly between countries: some countries classify them as prescription drugs or controlled substances, and their over-the-counter possession, sale, or use for competitive purposes may be illegal. Procurement for scientific research and medical purposes requires compliance with applicable regulations and ethical approvals. Exercise caution regarding non-medical and unsupervised use, emphasizing compliance with local laws and conducting all related procedures under the guidance of a medical professional.

11. Packaging, Labeling, and Transportation Focus

Compliant injectable oils should clearly indicate the product name, strength (e.g., 100mg/ml), batch number, production/expiration date, storage conditions, manufacturer information, compliance certification mark, and appropriate shipping and hazardous materials handling instructions on the outer packaging and label. During transportation, they must be protected from severe vibration, high temperatures, and sunlight. Cross-border transportation must comply with import and export control requirements.